Passage Bio Reports Strong Progress in FTD-GRN Gene Therapy Trial, Extends Cash Runway to 2027
PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) announced second-quarter 2025 results and reported key advancements in its upliFT-D clinical trial, including completion of dosing in the second cohort of …
Passage Bio Reports Strong Progress in FTD-GRN Gene Therapy Trial, Extends Cash Runway to 2027 Read More